Genexine Co. Ltd.
26 articles with Genexine Co. Ltd.
Genexine’s First-in-Class Therapeutic DNA Vaccine Shows Significant Potential to Extend Survival in Late-Stage Cervical Cancer
Genexine (KOSDAQ: 095700), today announced that GX-188E, its first-in-class proprietary DNA vaccine, demonstrated potent efficacy and favorable safety in patients with advanced cervical cancer in a phase 2 study when given in combination with KEYTRUDA® (pembrolizumab), MSD’s (Merck & Co., Inc., Rahway, NJ, USA) anti-PD-1 therapy.
Genexine selected for Late-Breaking Oral Presentation of Phase 2 Study of GX-188E in Combination with KEYTRUDA® (pembrolizumab) in Cervical Cancer at European Society for Medical Oncology (ESMO) Congress 2022
Genexine, announced that late-breaking results from the Phase 2 clinical trial study of its therapeutic DNA vaccine GX-188E in combination with MSD’s anti-PD-1 therapy, KEYTRUDA®, were selected for an oral presentation at the 2022 European Society for Medical Oncology Congress which is being held from September 9-13 in Paris, France.
Novartis' canakinumab failed again in non-small cell lung cancer while Anixa Biosciences, Palisade Bio and Genexine kicked off new trials.
Genexine Announces Dosing of First Patient in Phase 2 clinical trial with Triple Combination Therapy in Patients with Head and Neck Squamous Cell Carcinoma (HNSCC)
Genexine announced the dosing of the first patient in phase 2 clinical trial using triple combination therapy in patients with recurrent/metastatic HNSCC.
Genexine Announces Completion of Enrollment in Phase 3 Clinical Trial with Its Proprietary Long-acting Growth Hormone, GX-H9/TJ101 (Eftansomatropin alfa)
Genexine announced that its partner, I-Mab, recently completed patient enrollment in a phase 3 clinical trial of its proprietary long-acting growth hormone, eftansomatropin alfa, also known as GX-H9/TJ101, in China, taking it one step closer to commercialization in a key market.
Genexine reports encouraging top-line results of the Phase 1b/2 clinical trial with GX-I7 (efineptakin alfa) in refractory or recurrent (R/R) metastatic Triple Negative Breast Cancer
Genexine announced top-line results from the KEYNOTE-899 phase 1b/2 clinical trial of GX-I7 in combination with pembrolizumab.
Genexine Appoints Industry Veteran Neil Warma as Chief Executive Officer to Accelerate Global Growth, Product Commercialization and Innovation
Genexine a publicly traded, clinical stage biopharmaceutical company committed to the discovery and development of novel biologics for the treatment of unmet medical needs, announced the appointment of Neil Warma as its President and Chief Executive Officer.
Genexine announced that Neil Warma, CEO of Genexine will be presenting virtually at the H.C. Wainwright Global Investment Conference being held on May 23-26, 2022.
Genexine and NeoImmuneTech Announce Data Release for their Phase 1b/2 Study of GX-I7/NT-I7 (efineptakin alfa) and KEYTRUDA® (pembrolizumab) in patients with Triple-negative Breast Cancer
Genexine, Inc. and NeoImmuneTech, Inc. announced the release of data for the dose escalation phase of their Ph1b/2 study of GX-I7/NT-I7, a novel T cell amplifier, in combination with KEYTRUDA®, a leading checkpoint inhibitor, for the treatment of heavily pretreated patients with relapsed or refractory triple-negative breast cancer.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 24, 2020.
I-Mab and Genexine Announce China NMPA Clearance for Phase 2 Clinical Trial of TJ107/HyLeukin-7™ in Glioblastoma Multiforme
- I-Mab to initiate Phase 2 clinical trial in glioblastoma multiforme (GBM) in China - I-Mab and Genexine expand collaboration for development of TJ107/HyLeukin-7™
Genexine and NeoImmuneTech Announce Dosing of First Patient in the Combination Trial of Hyleukin-7™ with Merck’s KEYTRUDA® in Triple-Negative Breast Cancer
Genexine, Inc. (Genexine) and NeoImmuneTech, Inc. (NIT), a T cell-focused therapeutics company, today announced that the first patient has been dosed in a combination regimen trial to investigate the safety and efficacy of Hyleukin-7™, their T cell amplifier, in combination with Merck’s anti PD-1 therapy, KEYTRUDA
A Potential Global First-in-Class Long-Acting IL-7 for Chemotherapy induced Lymphopenia and Cancer Immunotherapy
Hyleukin-7 Selected as a Korea Drug Development Fund (KDDF) Project for Combination Trial with Merck’s KEYTRUDA®
Genexine will conduct a phase 1b/2 clinical trial to investigate the safety and efficacy of Hyleukin-7 treatment in combination with Merck’s anti PD-1 therapy, KEYTRUDA® in patients with triple-negative breast cancer.
NeoImmuneTech Announces Initiation of HyLeukin-7 Clinical Development for Cancer Patients in the U.S.
NeoImmuneTech, Inc. announced today the initiation of its first U.S. clinical trial.
NeoImmuneTech Announces a Clinical Trial Collaboration with a Global Leading Pharmaceutical Company to Evaluate HyLeukin-7 in Combination with a PD-L1 Checkpoint Inhibitor in Advanced High-Risk Skin Cancers
NeoImmuneTech have entered into an agreement with Roche to enable studies of a combination treatment in three advanced high-risk skin cancer types.
PharmaJet released positive interim results from the U.S. Army’s Phase I clinical trial of two hantavirus vaccines to prevent hemorrhagic fever with renal syndrome (HFRS).
PharmaJet®, the maker of innovative, needle-free injection technology, today announced a global license agreement with Genexine.
Under the terms of the agreement, I-Mab will provide an upfront payment in exchange for an exclusive license for development and commercialization rights of HyLeukin in greater China in the field of oncology.
Genexine Co. Ltd. Receives Approval To Initiate Phase Ib/II Trial Of GX-188E, HPV Therapeutic DNA Vaccine, In Combination With KEYTRUDA (Pembrolizumab), For The Treatment Of HPV-Induced Cervical Cancer